Stewardship Actions for Market issues in the National Disability Insurance Scheme: A Review of the Evidence
Evidence Base · 2019
DOI: 10.21307/eb-2019-001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence Base, 2019. Verfasst von Eleanor Malbon und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 102 Literaturangaben.
Abstract (Originalsprache)
As the Australian National Disability Insurance Scheme (NDIS) progresses through its implementation, calls for stewardship of the new disability market increase. As a personalisation scheme, the condition of the disability service markets is tied to the ability for people with disability to access care services. Market conditions such as thin markets, market gaps and market failure threaten the public policy goals of increased choice and control for NDIS participants. We review the evidence for interventions and other market stewardship actions that can be taken by government to steward a quasi-market that provides care or welfare services. We assess the breadth and quality of the evidence base and apply these findings to the case of the Australian NDIS. We conclude that there is sufficient evidence to take actions to steward the NDIS market, but that considerable resources and governance capacity are needed to do so.
Zitieren
APA
Malbon, E., Reeders, D., Carey, G., & Marjolin, A. (2019). Stewardship Actions for Market issues in the National Disability Insurance Scheme: A Review of the Evidence. Evidence Base. https://doi.org/10.21307/eb-2019-001
Vancouver
Malbon E, Reeders D, Carey G, Marjolin A. Stewardship Actions for Market issues in the National Disability Insurance Scheme: A Review of the Evidence. Evidence Base. 2019. doi:10.21307/eb-2019-001
BibTeX
@article{Malbon2019,
author = {Malbon, Eleanor and Reeders, Daniel and Carey, Gemma and Marjolin, Axelle},
title = {Stewardship Actions for Market issues in the National Disability Insurance Scheme: A Review of the Evidence},
journal = {Evidence Base},
year = {2019},
doi = {10.21307/eb-2019-001}
}
EUVIMED